Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer: insights from real-world data of a nationwide cohort
Linda Cucciniello(University of Udine), Fabio Puglisi(University of Udine), Claudia Bighin(Azienda Ospedaliera S.Maria), Eva Blondeaux(Ospedale Policlinico San Martino), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Filippo Montemurro(Roche (Switzerland)), Simona Gasparro(National Cancer Institute), Grazia Arpino(University of Naples Federico II), Alessandra Fabi(Agostino Gemelli University Polyclinic), Lorenzo Gerratana(National Cancer Institute), A. Ferzi, Valentina Sini(Ospedale di Santo Spirito), Lucia Del Mastro(Ospedale Policlinico San Martino), Stefania Russo(National Center for Oncological Hadrontherapy), Luca Boni(Ospedale Policlinico San Martino), Enrico Cortesi(Sapienza University of Rome), Andrea Fontana(Azienda Ospedaliera Universitaria Pisana), Arianna Dri(University of Udine), Palma Pugliese(Ospedale Sant'Anna), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
|The Lancet Oncology|2015|1.1k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k